1999
Started as India’s first independent product development company
2009
Commissioned oral solids manufacturing facility in Ambernath, India
2010
First ANDA filing
2011
First UK-MHRA inspection of oral solids facility
2013
First US FDA facility inspection
2014
First own ANDA approval
2017
Established Advagen Pharma in the US
2019
Acquired 15 ANDAs
Sixth successful US FDA inspection
$100 million growth capital commitment by General Atlantic
Acquired Impopharma Canada Ltd and established Rubicon Research Canada Ltd for nasal and pulmonary research
2020
Launch of Rubicon Consumer Healthcare
Launch of Rubicon Academy
2021
Acquired an oral liquid and nasal product manufacturing facility in Satara, Maharashtra